ArticleJournal of nanobiotechnology2026
Biomimetic hybrid nanocarriers hitchhike neutrophils for targeted ginsenoside Rc delivery to BMSCs: ameliorating postmenopausal osteoporosis via iron homeostasis regulation.
Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Postmenopausal osteoporosis (PMOP), a prevalent skeletal disorder among postmenopausal women, is hallmarked by heightened fracture susceptibility. Estrogen deficiency in this condition impairs the endogenous antioxidant defense system, triggering iron overload within the bone marrow mesenchymal stem cell (BMSC) niche and disrupting bone metabolic homeostasis. Guided by this mechanistic framework, we focused on ginsenoside Rc (Rc), a bioactive phytochemical endowed with capacities to enhance antioxidant defenses and potential iron-regulating activities. We engineered DT-NPNs/Rc via a pathogen-mimetic strategy, entailing hybridization of bacterial outer membrane vesicles (OMVs) with BMSC-derived membranes for encapsulation of Rc. These nanoconstructs exploit the bone marrow-homing properties of circulating neutrophils for hitchhiking, followed by specific internalization by BMSCs to achieve targeted Rc delivery. Functional assessments revealed that DT-NPNs/Rc mitigates lipid peroxidation through SIRT1/p53 axis, thereby restoring the osteogenic differentiation capacity of BMSCs under iron overload. Notably, in vivo studies confirmed that DT-NPNs/Rc effectively attenuates ovariectomy (OVX)-induced bone loss. Collectively, by overcoming the limitations of conventional delivery systems in targeting, DT-NPNs/Rc offered an innovative, highly efficient, and clinically translatable platform for PMOP treatment.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.